+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Animal Biotechnology Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4987142
  • Report
  • April 2021
  • Region: Global
  • 112 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Bayer AG
  • Biogenesis Bago
  • Heska Corporation
  • IDVet
  • Ivaoes, LLC
  • Pfizer Inc.
The Global Animal Biotechnology Market is expected to register a CAGR of 6.5% during the forecast period.

As per the data of the Centre for Disease Control and Prevention (CDC) in 2020, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. The virus was recently detected in mink on multiple farms of the Netherlands. Several studies are being undertaken to understand the connection between animals and the human transmission of the virus.

Moreover, COVID-19 pandemic 2020, had a dramatic effect throughout the world on animal healthcare systems. Due to the fear of the virus, many of the people avoiding visits to veterinary hospitals. Thus, with the reduction of hospital visits, resulted in delay in diagnosis and treatment is expected in the animals, leading to a decline in demand for animal management products.

Globally, biotechnology has improved animal feed, produced vaccines for livestock and improved diagnostics for diseases such as Bovine spongiform encephalopathy (BSE), foot-and-mouth disease and salmonella.

A significant rise in focus toward cloning and transgenic animals is expected to propel the market growth. For instance, according to a research article by NishuNishu et al., published in Animal Biotechnology 2020, globally, rapidly growing technologies in genomic knowledgebase have tremendously fastened the process of transgenesis. Adding to that, alteration of transgenic animal's genome to understand diseases in animals.

As per the report published by the US Food and Drug Administration (FDA), in 2017, scientists have successfully cloned many livestock species, such as cattle, swine, sheep, and goats. Globally, animal cloning has gained popularity and acceptance, as a method to produce genetically identical animals, which is expected to fuel the market growth.

In addition, as per Animal Free Research UK, in 2019, around 1,729,646 animals experiments were performed in United Kingdom which includes 4,227 experiments on 2,679 dogs, 2,850 experiments on 2,156 primates, 131 experiments on 28 cats and 10,512 experiments on 43 horses, respectively.

The market players in the animal biotechnology market are involving in various growth strategies, such as collaborations, partnerships, agreements, and mergers and acquisitions, in order to enhance the market presence. For instance, in 2020, Merck Animal Health signed a partnership agreement with Automazioni VX, Inc. (US) with aimed at the introduction of Innoject Pro, a newly designed subcutaneous chick vaccination technology. The technology will be utilized in combination with Merck Animal Health’s Innovax range of vaccines, which is used for protection against infectious diseases.

In addition to the aforementioned factor, increasing R&D activities by major market players, and the rising regulatory approvals are expected to propel the market growth over the forecast period.

Key Market Trends

Vaccines Segment is Expected to Show Better Growth Over the Forecast Period

The growth of the vaccine segment is mainly attributed to the rising burden of animal diseases. These diseases are naturally transmitted from animals to humans, due to the consumption of contaminated food and water or by direct contact with infected animals or humans. Vaccination is an effective way to reduce disease burden in animals and plays an important role in preventive health and disease control.

As per research studies, diverse coronaviruses can infect the domestic species from cattle, pigs, poultry, cats to dogs. Many of these infections are controlled by routine vaccination. But research on SARS-Cov-2 in animals is limited, but studies are underway to learn more about this virus can affect different animals.

Furthermore, globally, national animal disease control programmeswere reduced or even suspended. National activities on outbreak investigations, animal disease surveillance, and vaccination campaigns were not implemented. For instance, Australia’s Minister of Agriculture said that COVID-19 restrictions would affect the industry and government respond to an outbreak of African swine fever, regarding the early detection and reporting of the virus. In addition, African swine fever control efforts in Papua New Guinea were difficult to implement due to COVID-19 lockdown in the country.

According to a research article by Andrew W. Byrne et al., published in Frontiers in Veterinary Science 2019, Bovine tuberculosis (bTB) remains a prominent zoonotic pathogen on the world stage, with significant impacts on animal and human health, and economic well-being. Moreover, the increasing demand for meat and animal-based products, rising pet adoption and increasing awareness regarding animal health are expected to fuel the growth of the vaccine segment over the forecast period.

The market players are also investing in the vaccines development, which is also driving the market growth. For instance, in 2019, Boehringer Ingelheim started to develop the largest biotechnology site for veterinary vaccines in France, as its demand increased with growth in poultry consumption. The company invested EUR 200 million at the 15,000 m2 facility in Lyon, France. Thus, considering above mentioned factors it is expected to fuel the segment growth over the forecast period.

North America Dominates the Market and is Expected to do the Same over the Forecast Period

The major factors that are driving the Animal Biotechnology Market include increase in adoption of companion animals, increasing prevalence of diseases such as zoonosis, availability of advanced veterinary healthcare infrastructure available in the region and presence of key market players in the region.

In United States, the COVID-19 pandemic 2020 directly or indirectly disrupts activities to keep livestock animals healthy, including the prevention and control of diseases. Due to labour shortages, there was reduced capacity to work on animal health activities such as vaccination, maintaining good biosecurity, medical treatment of sick animals and prophylactic treatment. For instance, according to the United States Food and Drug Administration (USFDA), 6 of the 32 animal drug companies that make finished drugs or source active pharmaceutical ingredients in China for the market of the United States of America, have indicated that the supply chain disruptions could soon lead to shortages of medicines (American Veterinary Medical Association).

There are also increasing initiatives and campaigns implemented by the Canadian government to promote animal health, which may boost the demand for animal diagnostics in the coming years. For instance, the Canadian Veterinary Medical Association is involved in promoting animal welfare to ensure the optimal health of animals. Such activities are likely to influence the studied market growth in Canada

The data published by the American Pet Products Association, in 2018, states that the total pet healthcare expenditure has been estimated to be USD 72.13 billion, while that in 2017 was found to be USD 69.51 billion.

In February 2020, Zoetis Inc. acquired Ethos Diagnostic Science, a veterinary reference lab. By entering the veterinary reference laboratory space through the acquisitions of both Phoenix Lab and ZNLabs in 2019, Zoetis continues to grow its diagnostics presence to offer comprehensive and enhanced value to veterinarians in the United States. In addition, the growing awareness about animal health among the pet owners, rising government initiatives, and rise in product innovation (such as new vaccine launches) are some other factors propelling the growth of the animal biotechnology market in North America.

Competitive Landscape

The Animal Biotechnology Market is moderately consolidated and consists of few major players who are currently dominating the market. Some of the market players include Bayer AG, Boehringer Ingelheim GmbH, Merck & Co.,Inc., Zoetis Inc., Virbac and others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogenesis Bago
  • Heska Corporation
  • IDVet
  • Ivaoes, LLC
  • Pfizer Inc.

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Activities by Major Market Players
4.2.2 Growing Focus Towards Cloning & Transgenic Animals
4.3 Market Restraints
4.3.1 Ethical Issues Associated with Animal Biotechnology Products
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Diagnostic Tests
5.1.2 Reproductive & Genetic Products
5.1.3 Vaccines
5.1.4 Drugs
5.2 By Application
5.2.1 Development of Animal Pharmaceuticals
5.2.2 Food Safety and Drug Development
5.2.3 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Biogenesis Bago
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Ivaoes, LLC
6.1.5 Merck & Co.,Inc.
6.1.6 Pfizer Inc.
6.1.7 Santa Cruz Biotechnology, Inc.
6.1.8 Virbac
6.1.9 Zoetis Inc.
6.1.10 Idexx Laboratories
6.1.11 IDVet
6.1.12 Heska Corporation
6.1.13 INDICAL Bioscience GmbH
6.1.14 BioChek BV
6.1.15 Randox Laboratories Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Biogenesis Bago
  • Boehringer Ingelheim GmbH
  • Ivaoes, LLC
  • Merck & Co.,Inc.
  • Pfizer Inc.
  • Santa Cruz Biotechnology, Inc.
  • Virbac
  • Zoetis Inc.
  • Idexx Laboratories
  • IDVet
  • Heska Corporation
  • INDICAL Bioscience GmbH
  • BioChek BV
  • Randox Laboratories Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...